MA51221A - Composés de pyrazolopyridinone - Google Patents

Composés de pyrazolopyridinone

Info

Publication number
MA51221A
MA51221A MA051221A MA51221A MA51221A MA 51221 A MA51221 A MA 51221A MA 051221 A MA051221 A MA 051221A MA 51221 A MA51221 A MA 51221A MA 51221 A MA51221 A MA 51221A
Authority
MA
Morocco
Prior art keywords
pyrazolopyridinone
compounds
pyrazolopyridinone compounds
Prior art date
Application number
MA051221A
Other languages
English (en)
Inventor
Wing Shun Cheung
Haibing Guo
Qian Liu
Luoheng Qin
Zhao-Kui Wan
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MA51221A publication Critical patent/MA51221A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Cosmetics (AREA)
MA051221A 2017-11-24 2018-11-23 Composés de pyrazolopyridinone MA51221A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2017112836 2017-11-24

Publications (1)

Publication Number Publication Date
MA51221A true MA51221A (fr) 2020-10-07

Family

ID=66630494

Family Applications (1)

Application Number Title Priority Date Filing Date
MA051221A MA51221A (fr) 2017-11-24 2018-11-23 Composés de pyrazolopyridinone

Country Status (12)

Country Link
US (2) US11384099B2 (fr)
EP (1) EP3717483B1 (fr)
JP (1) JP7329510B2 (fr)
KR (1) KR102723359B1 (fr)
CN (1) CN111655689B (fr)
AU (1) AU2018370904B2 (fr)
BR (1) BR112020010004A2 (fr)
CA (1) CA3084528A1 (fr)
ES (1) ES2963339T3 (fr)
MA (1) MA51221A (fr)
MX (1) MX2020005342A (fr)
WO (1) WO2019101183A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11691970B2 (en) * 2017-11-24 2023-07-04 Janssen Pharmaceutica Nv Pyrazolopyridinone compounds
JP7689923B2 (ja) 2018-12-26 2025-06-09 ヤンセン ファーマシューティカ エヌ.ベー. チエノピリジノン化合物
US12441707B2 (en) 2019-12-30 2025-10-14 Tyra Biosciences, Inc. Indazole compounds
CN111454214B (zh) * 2020-05-27 2023-04-07 龙曦宁(上海)医药科技有限公司 一种2-甲氧基1-嘧啶乙胺盐酸盐的合成方法
TW202246284A (zh) * 2021-03-10 2022-12-01 大陸商山東軒竹醫藥科技有限公司 三并環類hpk1抑制劑及其用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5221683A (en) 1984-03-19 1993-06-22 The Rockefeller University Diaminopyridine compounds and methods of use
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
CA2744096C (fr) 1996-07-31 2013-07-30 Laboratory Corporation Of America Holdings Biomarqueurs et cibles de diagnostic, de pronostic et de traitement du cancer de la prostate
AUPQ969800A0 (en) * 2000-08-28 2000-09-21 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compound and pharmaceutical use thereof
ES2334641T3 (es) * 2000-09-01 2010-03-15 Novartis Vaccines And Diagnostics, Inc. Derivados aza heterociclicos y su uso terapeutico.
US20030028018A1 (en) 2000-09-11 2003-02-06 Chiron Coporation Quinolinone derivatives
PL211125B1 (pl) 2000-09-11 2012-04-30 Novartis Vaccines & Diagnostic Pochodne chinolinonu jako inhibitory kinazy tyrozynowej, kompozycje je zawierające i ich zastosowanie
JP3539424B2 (ja) * 2002-07-24 2004-07-07 日産自動車株式会社 電気自動車の制御装置
BR0313743A (pt) * 2002-08-23 2005-07-05 Chiron Corp Benzimidazol quinolinonas e usos destas
MXPA05004754A (es) 2002-11-13 2005-08-02 Chiron Corp Metodos para tratar cancer y metodos relacionados.
WO2005047244A2 (fr) 2003-11-07 2005-05-26 Chiron Corporation Inhibition de recepteur fgfr3 et traitement de myelome multiple
WO2012018909A1 (fr) 2010-08-04 2012-02-09 Takeda Pharmaceutical Company Limited Composés hétérocycliques condensés

Also Published As

Publication number Publication date
EP3717483A1 (fr) 2020-10-07
KR102723359B1 (ko) 2024-10-28
EP3717483A4 (fr) 2021-07-14
US20220340598A1 (en) 2022-10-27
BR112020010004A2 (pt) 2020-10-13
US11384099B2 (en) 2022-07-12
EP3717483B1 (fr) 2023-09-06
AU2018370904A1 (en) 2020-05-14
KR20200090828A (ko) 2020-07-29
JP7329510B2 (ja) 2023-08-18
ES2963339T3 (es) 2024-03-26
CA3084528A1 (fr) 2019-05-31
JP2021504332A (ja) 2021-02-15
AU2018370904B2 (en) 2023-09-21
US20210147446A1 (en) 2021-05-20
MX2020005342A (es) 2020-10-14
WO2019101183A1 (fr) 2019-05-31
CN111655689B (zh) 2023-01-06
CN111655689A (zh) 2020-09-11
RU2020120796A (ru) 2021-12-24

Similar Documents

Publication Publication Date Title
EP3691623A4 (fr) Composés de benzosulfonyle
EP3720430A4 (fr) Composés benzocarbonyle
EP3836923A4 (fr) Composés pyrrolo-dipyridine
MA52948A (fr) Composés
MA49701A (fr) Composés immunomodulateurs
MA51669A (fr) Composés
MA42293A (fr) Composés antibactériens
EP3532069A4 (fr) Composés aryl-amide phosphodiamide antiviraux
EP3474845A4 (fr) Composés immunomodulateurs
MA53003A (fr) Composés
MA44020A (fr) Composés antitumoraux
ME03419B (fr) Composés dihydroisoquinolinone substitués
EP3609871A4 (fr) Composés d'amide aryl cyclopropyl-amino-isoquinolinyl
MA50504A (fr) Composés antibactériens
PT4039675T (pt) Compostos de fenil-2-hidroxi-acetilamino-2-metil-fenilo
EP3728289A4 (fr) Composés optimisés
EP3464336A4 (fr) Composés
MA49621A (fr) Composés bifonctionnels
EP3405455A4 (fr) Composés de 2-oxindole
MA52946A (fr) Composés
EP3713941A4 (fr) Composés de pyrazolopyridinone
EP3717483A4 (fr) Composés de pyrazolopyridinone
MA49522A (fr) Nouveaux composés de quinoléinone
MA49885A (fr) Composés macrocycliques
EP3504269A4 (fr) Composés de fluoroélastomère